Literature DB >> 12488285

Off label use--label off use?

J Boos.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12488285     DOI： 10.1093/annonc/mdg035

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  What the paediatricians need--the launch of paediatric research in Europe.

Authors:  José Ramet
Journal:  Eur J Pediatr       Date:  2005-02-22       Impact factor: 3.183

2.  Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.

Authors:  Paul E Kalb; Paul E Greenberg
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists.

Authors:  Christine Fukada; Jillian Clare Kohler; Heather Boon; Zubin Austin; Murray Krahn
Journal:  Can Pharm J (Ott)       Date:  2012-11

4.  Off-label drug use in children.

Authors:  Surabhi S Jain; S B Bavdekar; Nithya J Gogtay; Pranjali A Sadawarte
Journal:  Indian J Pediatr       Date:  2008-09-22       Impact factor: 1.967

5.  Off-label drug use in a Pediatric Intensive Care Unit.

Authors:  S B Bavdekar; Pranjali A Sadawarte; Nithya J Gogtay; Surabhi S Jain; Sandhya Jadhav
Journal:  Indian J Pediatr       Date:  2009-11       Impact factor: 1.967

6.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

7.  The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.

Authors:  Marta Herrero Fernandez; Raquel Molina Villaverde; Monica Arroyo Yustos; Fatima Navarro Expósito; Jose Luis Lopez Gonzalez; Maria Rosario Luque Infantes; Melchor Alvarez-Mon Soto
Journal:  Front Pharmacol       Date:  2019-10-23       Impact factor: 5.810

Review 8.  A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.

Authors:  Vincenzo Raimondi; Nicolas Thomas Iannozzi; Jessica Burroughs-Garcìa; Denise Toscani; Paola Storti; Nicola Giuliani
Journal:  Explor Target Antitumor Ther       Date:  2022-08-31

Review 9.  Regulating off-label drug use in India: The arena for concern.

Authors:  Sukhvinder Singh Oberoi
Journal:  Perspect Clin Res       Date:  2015 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.